304 North Cardinal St.
Dorchester Center, MA 02124
304 North Cardinal St.
Dorchester Center, MA 02124
The first study to treat moderate-to-severe eczema in infants and children 6 months to 5 years old with a biologic drug (monoclonal antibody) rather than immune-suppressing medications shows the drug was highly effective in reducing the signs and symptoms of moderate-to-severe eczema, report researchers involved in a new multi-site international phase III study led by Northwestern Medicine.
A 16-week course of dupilumab, a medication that targets a key immune pathway in allergies, resulted in more than half the children having at least a 75% reduction in signs of eczema and highly significant reductions in itch with improved sleep.
This is the first large-scale, randomized, placebo-controlled trial of a monoclonal antibody in any skin disease, including eczema, in children as young as six months. The study, which included 31 sites in Europe and North America, was published in The Lancet.
Study: Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial. Image Credit: Aisylu Ahmadieva / Shutterstock
“Preschoolers who are constantly scratching, awake multiple times a night with their parents, irritable and markedly curtailed in their ability to do what other children their ages can do improved to the extent that they sleep through the night, change their personalities and have a normal life — as babies and children should,” said lead study author Dr. Amy Paller, chair of dermatology at Northwestern University Feinberg School of Medicine and an attending physician at Ann & Robert H. Lurie Children’s Hospital of Chicago.
Eczema, also known as atopic dermatitis, is a chronic inflammatory skin disorder characterized by red, dry, often oozing skin and itch that can profoundly affect the lives of affected patients and their families.
An estimated 19% or more of all children under six years of age have eczema, and 85 to 90% of individuals affected overall with eczema have the onset of disease during the first five years of life.
The children’s debilitating itch leads to sleep disturbance, poor neurocognitive development, and, on average, a full night of sleep lost per week.
“The ability to take this drug will significantly improve the quality of life for infants and young children who suffer tremendously with this disease,” Paller said. “Atopic dermatitis or eczema is so much more than just itchy skin. It is a devastating disease. The quality of life of severe eczema — not only for the child but also parents — is equivalent to many life-threatening diseases.”
As a result of this study, this medication is now available to infants and preschoolers as young as six months. In addition, it has “an outstanding safety profile” and does not even require any laboratory tests before starting the medication, Paller said.
Although one-half to two-thirds of young children with eczema have mild symptoms, which can be handled with steroid ointment and moisturizers, the other one-third or more have a moderate-to-severe disease and require more aggressive management.
“Up to now, all we have had to treat more severe eczema is immune-suppressing medications, such as oral steroids, which we try to avoid in children, because they are associated with so many side effects and thus are not a preferred treatment for a chronic skin disease,” Paller said. “The potential long-term impact on the development of the immune system in young children is also of concern with these immunosuppressants.”
During the past few years, a new medication called dupilumab, the first “biologic” drug to treat eczema in a targeted manner, meaning a narrow attack on just what scientists have found is causing the manifestations of the disease in the skin. This medication was effective and safe in studies with adults, adolescents, and other school-aged children.
“But the group in whom we worry the most about safety — those under 5 — had not been tested and were unable to get this medication,” Paller said.
The parent or a health care provider gives the child a monthly shot to administer the medication.
“The effect for most of these younger children is dramatic and at least as good as we’ve seen with the risky immunosuppressant medications,” Paller said.
This medication has also been shown to be effective for treating asthma, gastrointestinal manifestations of allergy, and other allergy-mediated problems but is not yet approved for these indications in infants and young children.
In fact, 66% of children in this trial had developed eczema during the first six months of life. In addition, by the time of initiating the dupilumab, more than 80% had already developed at least one allergic disorder, such as asthma or food allergy.
“By treating more aggressively to calm the immune system activation in these young children with early, severe eczema, we may also reduce the risk of their developing a range of allergic problems, changing their life beyond improving eczema,” Paller said. “These associated allergic issues most often begin after the eczema starts.”
Children were randomized to receive either a placebo injection or the dupilumab (weight-based dosing) every four weeks for 16 weeks. Only children who were not responding adequately to topical medications were allowed to enroll, and they had to be highly severe, even with the topical medications.
As a result of the study, Paller said, scientists and physicians can start to understand better the relationships between eczema and a variety of allergic disorders. In addition, they can consider the possibility of using this medication for other conditions that affect these very young children.
The trial was sponsored by Regeneron Pharmaceuticals, Inc. and Sanofi, who jointly developed dupilumab.
Source: Northwestern University